Holen Sie sich die Stockscreener-App
1.44
4.35%
0.06
Schlusskurs vom Vortag:
$1.38
Offen:
$1.4
24-Stunden-Volumen:
668.87K
Relative Volume:
0.77
Marktkapitalisierung:
$145.10M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-2.7692
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+7.46%
1M Leistung:
-6.49%
6M Leistung:
-31.10%
1J Leistung:
+9.92%
1-Tages-Spanne:
$1.37
$1.455
1-Wochen-Bereich:
$1.27
$1.49
52-Wochen-Spanne:
$0.9515
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.44 | 145.10M | 27.08M | -37.00M | -18.46M | -0.52 |
|
TMO
Thermo Fisher Scientific Inc
|
423.55 | 160.15B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
199.05 | 141.09B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
471.90 | 35.45B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
108.63 | 30.37B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.48 | 26.50B | 15.41B | 1.37B | 2.11B | 7.50 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Acquired by JPMorgan Chase & Co. - Defense World
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MyChesCo
Geode Capital Management LLC Reduces Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
XTX Topco Ltd Acquires New Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 34.8% in April - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Aclaris Therapeutics Names Jesse Hall Chief Medical Officer - marketscreener.com
Aclaris Therapeutics (ACRS) Welcomes Jesse Hall as Chief Medical Officer | ACRS Stock News - GuruFocus
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - marketscreener.com
Aclaris Therapeutics appoints new Chief Medical Officer - Investing.com
Aclaris Strengthens Leadership: Humira and Prolia Developer Takes CMO Role to Advance Immunology Pipeline - Stock Titan
Androgenetic Alopecia Treatment Market Generated - openPR.com
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $11.67 Average Target Price from Brokerages - Defense World
Strong week for Aclaris Therapeutics (NASDAQ:ACRS) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Aclaris Therapeutics Inc [ACRS] Records 50-Day SMA of $1.6630 - knoxdaily.com
The time has not yet come to remove your chips from the table: Aclaris Therapeutics Inc (ACRS) - Sete News
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Trading Day Triumph: Aclaris Therapeutics Inc (ACRS) Ends at 1.10, a -2.65 Surge/Plunge - DWinneX
Some Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shareholders Look For Exit As Shares Take 31% Pounding - simplywall.st
Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 - Yahoo Finance
FDA clears Aclaris’ new drug for clinical trial - Investing.com Australia
FDA clears Aclaris’ new drug for clinical trial By Investing.com - Investing.com South Africa
ACRS’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Aclaris Therapeutics gets FDA nod to begin trial of ATI-052 - MSN
Aclaris Gets FDA Clearance for Clinical Trial of Immuno-Inflammatory Treatment - marketscreener.com
Aclaris Therapeutics (ACRS) Gains on FDA Clearance for ATI-052 Trial - GuruFocus
Aclaris gets FDA nod to begin trial of ATI-052 (ACRS:NASDAQ) - Seeking Alpha
Aclaris Therapeutics Shares Rise After FDA Clear ATI-052 for Trial - marketscreener.com
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody - The Manila Times
Aclaris Therapeutics (ACRS) Gains FDA Clearance for Novel Antibody Trial | ACRS Stock News - GuruFocus
Aclaris Therapeutics Secures U.S. Food and Drug - GlobeNewswire
Aclaris Therapeutics (ACRS) Gains on FDA Clearance for ATI-052 T - GuruFocus
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
Arthralgia Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis - The Globe and Mail
Commonwealth Equity Services LLC Buys New Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor - MSN
Aclaris Therapeutics Inc (ACRS) Has Recovered 21.49% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Aclaris Therapeutics Inc [ACRS] Director makes an insider purchase of 666,666 shares worth 1.5 million. - knoxdaily.com
Raymond James Financial Inc. Acquires Shares of 154,351 Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Institutional investors in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) see US$21m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Charles Schwab Investment Management Inc. Makes New Investment in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.67 - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Increase in Short Interest - Defense World
Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely? - Yahoo Finance
HighTower Advisors LLC Has $652,000 Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris at H.C. Wainwright Conference: Strategic Moves in Immuno-Inflammatory Diseases - Investing.com India
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aclaris Therapeutics Inc-Aktie (ACRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):